Immunobiomarkers for immunotherapy in non-small cell lung carcinoma

Specific immunotherapies have been developed, and they are approved by the FDA for clinical anti-cancer therapy. These agents are mainly monoclonal antibodies. Prior to applying these immunotherapy agents, one must determine the level of expression of target biomarkers on tumor cells by using specific IHC stains. Lack of knowledge of immunotherapy could have a negative impact on patient care. We will discuss: (1) update on how immunotherapy has rapidly integrated into standard care in oncology, (2) issues in the immunotherapy paradigm, including evolving standards of care in the multidisciplinary management of cancer patients, (3) selection criteria of tumor sample for IHC testing, particularly the adequacy criteria for PD-L1/PD-1 IHC testing.

Biography
Qing Kay Li is working as an Associate Professor of Pathology at the Johns Hopkins University, School of Medicine. She has the American Board of Pathology certification in Anatomic and Clinical Pathology, and subspecialty certification in Cytopathology. Her areas of clinical expertise include surgical pathology and cytopathology. She is also a Faculty Member and Co-PI at the Johns Hopkins Biomarker Discovery Center. Her research interests focuses on the application of advanced cellular and molecular techniques in the field of cytopathology and cancer biology, particularly in the field of early detection of lung and prostate cancer.

qli23@jhmi.edu

Notes: